

This project was funded by Walsall Health. Thanks are due to Mr DC Crothers (Biochemistry Department, Manor Hospital) for help with data analysis.

This audit was carried out at the Manor Hospital,

Walsall (Walsall Hospitals NHS Trust), in collaboration with Walsall Heartcare (cardiac rehabilitation centre), having been commissioned by Walsall Health.

- 1 Smith R. The scientific basis of health services. *BMJ* 1995; 311: 961–2.
- 2 Smith J, Channer KS. Increasing prescription of drugs for secondary prevention after myocardial infarction. *BMJ* 1995; 311: 917–918.
- 3 Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S). *Lancet* 1994; 344: 1383–9.
- 4 Scandinavian Simvastatin Survival Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study(4S). *Lancet* 1995; 345: 1274–5.
- 5 Oliver M, Poole-Wilson P, Shepherd J, Tikkanen MJ. Lower patients' cholesterol now. *BMJ* 1995; 310: 1280–1.
- 6 Channer KS. Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach. *Postgrad Med J* 1995; 71: 321–2.
- 7 Saltissi S, Mushahwar S. Myocardial infarction: prophylaxis after infarction. *Prescribers' J* 1995; 35: 149–58.
- 8 Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. *Circulation* 1995; 91: 2274–82.
- 9 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. *N Engl J Med* 1995; 333: 1301–7.
- 10 Goldbourt U, Behar S, Reicher-Reiss H, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial). *Am J Cardiol* 1993; 71: 909–15.
- 11 McGovern ME. Clinical trials with pravastatin: reduction in morbidity and mortality (review). *Br J Cardiol* 1995; 2 (suppl 2): S13–4.
- 12 Criteria Committee, New York Heart Association, Inc. *Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis*, 6th edn. Boston: Little, Brown and Co, 1964; p 114.
- 13 Keech A, Collins R, MacMahon, et al. Three-year follow-up of the Oxford cholesterol study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. *Eur Heart J* 1994; 15: 255–69.
- 14 Ryder REJ, Hayes TM, Mulligan IP, et al. How soon after myocardial infarction should plasma lipid values be assessed? *BMJ* 1984; 289: 1651–3.
- 15 Jonsson B, Johannesson M, Kjekshus J, et al. Cost effectiveness of cholesterol lowering. *Eur Heart J* 1996; 17: 1001–7.
- 16 Davey Smith G, Pekkanen J. Scandinavian simvastatin survival study (letter). *Lancet* 1994; 344: 1766.

Medical Anniversary

GEORGE MINOT, 2 DECEMBER 1885

George Minot (1885 – 1950) was born in Boston, Massachusetts, son of a local doctor. He became MD (Harvard) (1912) and spent his working life as a haematologist. He showed the value of liver (and later vitamin B12) in the treatment of pernicious anaemia, for which he shared the Nobel prize with William Murphy and Dr Whipple in 1934. He died on 25 February 1950. – *DG James*